190 related articles for article (PubMed ID: 7575645)
1. Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites.
Ching MS; Blake CL; Ghabrial H; Ellis SW; Lennard MS; Tucker GT; Smallwood RA
Biochem Pharmacol; 1995 Sep; 50(6):833-7. PubMed ID: 7575645
[TBL] [Abstract][Full Text] [Related]
2. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes.
Nielsen TL; Rasmussen BB; Flinois JP; Beaune P; Brosen K
J Pharmacol Exp Ther; 1999 Apr; 289(1):31-7. PubMed ID: 10086984
[TBL] [Abstract][Full Text] [Related]
3. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6.
Madeira M; Levine M; Chang TK; Mirfazaelian A; Bellward GD
Drug Metab Dispos; 2004 Apr; 32(4):460-7. PubMed ID: 16680870
[TBL] [Abstract][Full Text] [Related]
4. Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast.
Ellis SW; Ching MS; Watson PF; Henderson CJ; Simula AP; Lennard MS; Tucker GT; Woods HF
Biochem Pharmacol; 1992 Aug; 44(4):617-20. PubMed ID: 1510710
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1.
Schmider J; Greenblatt DJ; Fogelman SM; von Moltke LL; Shader RI
Biopharm Drug Dispos; 1997 Apr; 18(3):227-40. PubMed ID: 9113345
[TBL] [Abstract][Full Text] [Related]
6. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.
Kerry NL; Somogyi AA; Bochner F; Mikus G
Br J Clin Pharmacol; 1994 Sep; 38(3):243-8. PubMed ID: 7826826
[TBL] [Abstract][Full Text] [Related]
7. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.
Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN
Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885
[TBL] [Abstract][Full Text] [Related]
8. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation.
Kudo S; Odomi M
Eur J Clin Pharmacol; 1998 May; 54(3):253-9. PubMed ID: 9681669
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2.
Haritos VS; Ching MS; Ghabrial H; Gross AS; Taavitsainen P; Pelkonen O; Battaglia SE; Smallwood RA; Ahokas JT
Pharmacogenetics; 1998 Oct; 8(5):423-32. PubMed ID: 9825834
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans.
Jacqz-Aigrain E; Funck-Brentano C; Cresteil T
Pharmacogenetics; 1993 Aug; 3(4):197-204. PubMed ID: 8220439
[TBL] [Abstract][Full Text] [Related]
11. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily.
Gorski JC; Jones DR; Wrighton SA; Hall SD
Biochem Pharmacol; 1994 Jul; 48(1):173-82. PubMed ID: 8043020
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
Schadel M; Wu D; Otton SV; Kalow W; Sellers EM
J Clin Psychopharmacol; 1995 Aug; 15(4):263-9. PubMed ID: 7593709
[TBL] [Abstract][Full Text] [Related]
13. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.
Halliday RC; Jones BC; Smith DA; Kitteringham NR; Park BK
Br J Clin Pharmacol; 1995 Oct; 40(4):369-78. PubMed ID: 8554939
[TBL] [Abstract][Full Text] [Related]
14. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.
Volotinen M; Turpeinen M; Tolonen A; Uusitalo J; Mäenpää J; Pelkonen O
Drug Metab Dispos; 2007 Jul; 35(7):1135-41. PubMed ID: 17431033
[TBL] [Abstract][Full Text] [Related]
15. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach.
Delaporte E; Slaughter DE; Egan MA; Gatto GJ; Santos A; Shelley J; Price E; Howells L; Dean DC; Rodrigues AD
J Biomol Screen; 2001 Aug; 6(4):225-31. PubMed ID: 11689122
[TBL] [Abstract][Full Text] [Related]
16. Measurement of liver microsomal cytochrome p450 (CYP2D6) activity using [O-methyl-14C]dextromethorphan.
Rodrigues AD; Kukulka MJ; Surber BW; Thomas SB; Uchic JT; Rotert GA; Michel G; Thome-Kromer B; Machinist JM
Anal Biochem; 1994 Jun; 219(2):309-20. PubMed ID: 8080088
[TBL] [Abstract][Full Text] [Related]
17. 2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6.
Ewald AH; Maurer HH
Toxicol Lett; 2008 Dec; 183(1-3):52-7. PubMed ID: 18938231
[TBL] [Abstract][Full Text] [Related]
18. Expression, purification, and characterization of mouse CYP2d22.
Yu AM; Haining RL
Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
[TBL] [Abstract][Full Text] [Related]
19. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
20. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
Mankowski DC
Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
